Stockscreener 앱 받기
27.96
0.39%
-0.11
전일 마감가:
$28.07
열려 있는:
$28.71
하루 거래량:
650.43K
Relative Volume:
0.41
시가총액:
$1.63B
수익:
$32.87M
순이익/손실:
$674.31M
주가수익비율:
2.4613
EPS:
11.36
순현금흐름:
$-330.11M
1주 성능:
+5.39%
1개월 성능:
+0.58%
6개월 성능:
-23.63%
1년 성능:
-16.04%
1일 변동 폭
$27.76
$28.97
1주일 범위
$26.04
$28.97
52주 변동 폭
$22.24
$46.00
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
명칭
Agios Pharmaceuticals Inc
전화
617-649-8600
주소
88 SIDNEY STREET, CAMBRIDGE, MA
Compare AGIO vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
27.96 | 1.64B | 32.87M | 674.31M | -330.11M | 11.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-24 | 개시 | Truist | Buy |
| 2025-11-20 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-11-19 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-24 | 개시 | H.C. Wainwright | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-09-27 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-02-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-03 | 개시 | Piper Sandler | Overweight |
| 2022-11-17 | 업그레이드 | Goldman | Sell → Neutral |
| 2022-07-27 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-03 | 개시 | BofA Securities | Buy |
| 2021-07-30 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-07-01 | 개시 | Raymond James | Mkt Perform |
| 2021-06-10 | 개시 | H.C. Wainwright | Buy |
| 2021-03-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-03-01 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-02-26 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-10-22 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2020-03-04 | 개시 | Barclays | Equal Weight |
| 2019-11-26 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-09-23 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-05-23 | 재개 | Goldman | Neutral |
| 2019-02-15 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2018-09-25 | 개시 | Leerink Partners | Mkt Perform |
| 2018-05-23 | 개시 | Citigroup | Buy |
| 2018-04-11 | 재확인 | Credit Suisse | Outperform |
| 2018-02-15 | 재확인 | Needham | Buy |
| 2018-02-15 | 재확인 | SunTrust | Buy |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-08-10 | 재확인 | Needham | Buy |
| 2017-08-08 | 재확인 | SunTrust | Buy |
| 2017-08-02 | 업그레이드 | Leerink Partners | Mkt Perform → Outperform |
| 2017-06-26 | 다운그레이드 | Janney | Buy → Neutral |
| 2017-01-17 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2016-10-24 | 개시 | Needham | Buy |
| 2016-06-13 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2016-05-18 | 재확인 | SunTrust | Buy |
모두보기
Agios Pharmaceuticals Inc 주식(AGIO)의 최신 뉴스
STATE STREET CORP Acquires Additional Shares in Agios Pharmaceuticals Inc - GuruFocus
Agios Pharmaceuticals Incurs Narrower-Than-Expected Q4 Loss - Finviz
Brokers Offer Predictions for AGIO FY2030 Earnings - MarketBeat
Decoding Agios Pharmaceuticals Inc (AGIO): A Strategic SWOT Insi - GuruFocus
Agios Q4 2025 slides: PYRUKYND revenue surges 86%, thalassemia launch underway - Investing.com Canada
Decoding Agios Pharmaceuticals Inc (AGIO): A Strategic SWOT Insight - GuruFocus
Agios Pharmaceuticals (AGIO) Files Automatic Mixed Securities Shelf - GuruFocus
Agios Pharmaceuticals Inc (AGIO) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Does Agios Pharmaceuticals Inc. have a competitive edgeRate Cut & Smart Swing Trading Techniques - mfd.ru
Agios Pharmaceuticals Inc (AGIO) Q4 2025 Earnings Call Highlight - GuruFocus
Does Agios Pharmaceuticals Inc. have high return on assetsInflation Watch & Smart Allocation Stock Reports - mfd.ru
AGIO: HC Wainwright & Co. Raises Price Target to $65 with Buy Ra - GuruFocus
Truist Securities raises Agios Pharma stock price target to $39 on pipeline progress - Investing.com Canada
HC Wainwright Issues Positive Forecast for Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price - MarketBeat
Agios Pharmaceuticals (NASDAQ:AGIO) Posts Earnings Results, Beats Expectations By $0.11 EPS - MarketBeat
Agios Pharmaceuticals: Early Aqvesme Traction and REMS-Driven Uptake Support Robust Mitapivat Growth and Buy Rating - TipRanks
Earnings call transcript: Agios Pharm Q4 2025 sees strong revenue growth - Investing.com Canada
AGIO: Strong 2025 growth, ACTIVASE launch momentum, and key pipeline catalysts set for 2026 - TradingView
AGIOS PHARMACEUTICALS, INC. SEC 10-K Report - TradingView
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Agios Pharmaceuticals Inc (NASDAQ:AGIO) Reports Q4 2025 Revenue Beat and Narrower Loss - ChartMill
Agios Pharmaceuticals: Q4 Earnings Snapshot - kare11.com
Agios Pharmaceuticals: Fourth Quarter Earnings Overview - Bitget
Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - The Manila Times
Agios Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Availability of AQVESME™ for Thalassemia - Quiver Quantitative
Earnings Flash (AGIO) Agios Pharmaceuticals, Inc. Reports Q4 Revenue $20.0M, vs. FactSet Est of $12.1M - marketscreener.com
Press Release: Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - 富途牛牛
Avoiding Lag: Real-Time Signals in (AGIO) Movement - Stock Traders Daily
Agios Pharm set to report earnings amid thalassemia drug rollout By Investing.com - Investing.com Canada
Analyst Upgrade: Is Agios Pharmaceuticals Inc stock showing strong momentumRate Hike & Community Supported Trade Ideas - baoquankhu1.vn
Agios Pharmaceuticals, Inc. (AGIO) Stock Analysis: Unpacking a Potential 36% Upside for Investors - DirectorsTalk Interviews
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Agios Pharmaceuticals (AGIO) Valuation Check After Extended Share Price Weakness - Sahm
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Finviz
Agios Pharmaceuticals (AGIO) Projected to Post Earnings on Thursday - MarketBeat
Agios Pharmaceuticals (NASDAQ:AGIO) Share Price Crosses Below 200 Day Moving AverageTime to Sell? - MarketBeat
Agios Pharmaceuticals (AGIO): Investor Outlook On A Biotech With 30.5% Upside Potential - DirectorsTalk Interviews
Discipline and Rules-Based Execution in AGIO Response - Stock Traders Daily
Bull Bear: Does ProShares Trust ProShares Ultra Energy stock benefit from AI growthTrade Analysis Report & Intraday High Probability Alerts - baoquankhu1.vn
Arrowhead gains, Agios drops as drug developers end 2025 up 34% - BioWorld MedTech
Recap Report: Is Agios Pharmaceuticals Inc stock showing strong momentumDividend Hike & Low Drawdown Investment Ideas - baoquankhu1.vn
Agios begins U.S. launch of thalassemia drug following FDA approval By Investing.com - Investing.com Nigeria
Swing Trade: Is Agios Pharmaceuticals Inc stock overvalued or fairly pricedMarket Risk Report & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Aug Summary: Does Agios Pharmaceuticals Inc have a competitive edge2025 Support & Resistance & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET - The Manila Times
Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET - GlobeNewswire Inc.
BofA Securities Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $35 - 富途牛牛
Sickle Cell Disease Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | BRL Medicine, Oryzon Genomics, GlaxoSmithKline, Agios Pharma, Beam Therapeutics, Graphite Bio, Roche - Barchart.com
Analysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Agios Pharma (AGIO) and Henry Schein (HSIC) - The Globe and Mail
Is Agios Pharmaceuticals (AGIO) Offering A Compelling Entry Point After Recent Share Price Swings - Yahoo Finance
Agios Pharmaceuticals, Inc. (AGIO): A Bull Case Theory - Finviz
Agios Pharmaceuticals Inc (AGIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Agios Pharmaceuticals Inc 주식 (AGIO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Milanova Tsveta | Chief Commercial Officer |
Jan 05 '26 |
Sale |
27.02 |
2,872 |
77,601 |
34,793 |
1.12%
0.87%
자본화:
|
볼륨(24시간):